LRRK2 and Parkinson disease: There is no longer debate as to whether small-molecule kinase inhibitors can be highly selective and clinically efficacious.35 Tremendous efforts have focused on the identification of small-molecule kinase inhibitors that selectively target LRRK2 kinase activity to bring enzymatic function back to normal (e.g., WT), or ablate activity altogether, in the hopes of a neuroprotection strategy for PD.